Teva Pharmaceutical Industries Ltd
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $13.27B · View financials
Decision snapshot: Teva Pharmaceutical Industries Ltd stock price vs AVY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVY's multiple
Needs EPS (TTM), AVY P/E.
Implied fair value · at Teva Pharmaceutical Industries Ltd's multiple
Needs Teva Pharmaceutical Industries Ltd P/E.
Engine logicTeva Pharmaceutical Industries Ltdvalued onAVY’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Teva Pharmaceutical Industries Ltd Latest annual filing · AVY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Four fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 78% equity / 22% debt · EV / Revenue 1.90x · EV / EBITDA 12.38x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LTD · implied price per share
Reporting currency could not be verified.
AVERY DENNISON CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Teva Pharmaceutical Industries Ltd · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
1.66x
Net debt / EBITDA
Leverage against operating earnings
—
2.60x
Cash and equivalents
Liquid reserves on the balance sheet
—
$202.80M
Total debt
Interest-bearing obligations outstanding
—
$3.72B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
3M CO
Teva Pharmaceutical Industries Ltd vs MMM
EASTMAN CHEMICAL CO
Teva Pharmaceutical Industries Ltd vs EMN
ILLINOIS TOOL WORKS INC
Teva Pharmaceutical Industries Ltd vs ITW
RPM INTERNATIONAL INC/DE/
Teva Pharmaceutical Industries Ltd vs RPM
BRADY CORP
Teva Pharmaceutical Industries Ltd vs BRC
METTLER TOLEDO INTERNATIONAL INC/
Teva Pharmaceutical Industries Ltd vs MTD
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.